Thermo Fisher Scientific (TMO): Sector Reads Convey Confidence in End-Market Growth - Leerink

Leerink Partners analyst, Puneet Souda, reiterated his Outperform rating on shares of Thermo Fisher Scientific (NYSE: TMO) after two recent events gave the analyst confidence in TMO's ability to drive ~5% organic sales and double digit EPS growth:

1)Agilent's fourth quarter report delivered 16% biopharma growth, suggesting that as of October 31st (A's off-cycle 4Q16 close), biopharma end-market growth in the sector remains not only healthy but also accelerated at a time when the Street was getting cautious on it

2) meeting with TMO's Senior Director of Investor Relations, Rafael Tajeda, to discuss the overall business which gave the analyst confidence in TMO's ability to deliver, despite any uncertainty caused by the U.S. election and the pending NIH funding appropriations

No change to the price target of $175.

For an analyst ratings summary and ratings history on Thermo Fisher Scientific click here. For more ratings news on Thermo Fisher Scientific click here.

Shares of Thermo Fisher Scientific closed at $148.88 yesterday.

You May Also Be Interested In

• Tyler Tech (TYL) PT Raised to $500 at Oppenheimer
• Meta Platforms Inc. (META) PT Lowered to $575 at UBS, 'shares are offering a 3-to-1 skew'
• Sage Therapeutics (SAGE) PT Lowered to $18 at Truist Securities